Diagnostics and Genomics — Operating Income (Loss)
Agilent Technologies Diagnostics and Genomics — Operating Income (Loss) increased by 34.3% to $94.00M in Q3 2024 compared to the prior quarter. Year-over-year, this metric grew by 17.5%, from $80.00M to $94.00M. Over 3 years (FY 2021 to FY 2024), Diagnostics and Genomics — Operating Income (Loss) shows an upward trend with a 5.4% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates improved operational efficiency, better cost management, or higher margins on products sold.
Detailed definition
This represents the profit or loss generated by the diagnostics and genomics segment after deducting operating expenses...
Peer comparison
Standard measure of segment profitability used across all public companies to compare operational performance.
a_segment_diagnostics_and_genomics_operating_income_lossHistorical Data
| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $69.00M | $78.00M | $71.00M | $68.00M | $91.00M | $73.00M | $69.00M | $59.00M | $73.00M | $84.00M | $80.00M | $70.00M | $86.00M | $70.00M | $94.00M |
| QoQ Change | — | +13.0% | -9.0% | -4.2% | +33.8% | -19.8% | -5.5% | -14.5% | +23.7% | +15.1% | -4.8% | -12.5% | +22.9% | -18.6% | +34.3% |
| YoY Change | — | — | — | — | +31.9% | -6.4% | -2.8% | -13.2% | -19.8% | +15.1% | +15.9% | +18.6% | +17.8% | -16.7% | +17.5% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Agilent Technologies's diagnostics and genomics — operating income (loss)?
- Agilent Technologies (A) reported diagnostics and genomics — operating income (loss) of $94.00M in Q3 2024.
- How has Agilent Technologies's diagnostics and genomics — operating income (loss) changed year-over-year?
- Agilent Technologies's diagnostics and genomics — operating income (loss) increased by 17.5% year-over-year, from $80.00M to $94.00M.
- What is the long-term trend for Agilent Technologies's diagnostics and genomics — operating income (loss)?
- Over 3 years (2021 to 2024), Agilent Technologies's diagnostics and genomics — operating income (loss) has grown at a 5.4% compound annual growth rate (CAGR), from $273.00M to $320.00M.
- What does diagnostics and genomics — operating income (loss) mean?
- The profit or loss earned from the core operations of the diagnostics and genomics segment.